BNET Industries
Market Cap:$403.1M
Last Fiscal Year Sales:$12.6M
- Public
- US
Dow Jones Description
Developer of Drugs for Cancer & Infectious Disease Treatment
Number of Employees 181
Contact Information
1180 Veterans Blvd
South San Francisco, California 94080-4811
(650) 624-1100
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Rigel reports $26.7M loss in Q3
-
After-Hours Movers 9/16: ARKR Higher; CKR, RIGL, VVUS, ORCL, EK, DBRN Lower
-
Rigel Pharmaceuticals loses $29.9M in Q2
News & Analysis
Filter by
rigel pharmaceuticals inc. - All News and Analysis
Rigel Pharma: The Importance of Knowing Your Stock
Stone Fox Capital submits: Last Thursday night, Rigel Pharma RIGL released disappointing results on its TASKi3 Phase 2b study on Rheumatoid Arthritis (RA). The results showed that the placebo worked basically as well as the R788 pill. Now here is where you need to understand the stock and what was...
Rigel Pharmaceuticals: A Game Changer in the Works?
Dr. Anthony submits: With the impending announcement of the Phase IIb data for Rigel's RIGL lead compound R-788, I thought I would share my analysis. Rheumatoid Arthritis is a chronic debilitating disease that requires life-long treatment, which makes it a lucrative market but also at the same time very competitive....
Rigel and Seattle Genetics: The Delicate Art of Expectation Management
Ohad Hammer submits: In my previous article, I discussed the pharmaceutical industry’s race after approved drugs and late stage agents with proof of concept in humans. I mentioned Rigel’s RIGL lead drug, R788, as a likely target for collaboration due to its impressive activity, the huge addressable market and the...
Rigel Still on Track, And Has Pfizer Found Its Next Blockbuster?
Ohad Hammer submits: In the pharmaceutical industry, 2008 will probably be marked by the big pharmas’ insatiable appetite for new drugs. Threatened by fierce generic competition, the pharmaceutical giants were not only eager to pay generous acquisition premiums for marketed products, but were also willing to pay a lot of...
Rigel's Punishment May Prove Short-Sighted
EP Vantage submits: Rigel Pharmceuticals' RIGL shares have lost almost half their value this week since the release of fresh data from a phase II study of its lead product, R788 in rheumatoid arthritis, which considering the new information was neither overwhelmingly negative, nor entirely new, seems an overly severe...
My Model Biotech Picks: What's Hot and What's Not
A. Reza Saadat submits: Analyzing the performance of my previous picks is by far my favorite part of writing this blog. It has on many occasions allowed be to learn from my mistakes.I have moved the numbers to Google docs so that they are easier to read. Here is...
Wednesday Options Update: CHK, MER, RIGL, MYL, HRS, IR, LIZ
Rebecca Engmann Darst contributed to this report. Chesapeake Energy CHK – Highly intriguing call-spread activity to report this morning out of oil and natural gas extractor Chesapeake Energy, whose shares rose 2% to $45.79 following mixed oil inventory data. Chesapeake shares are more than $23 off their high of July...
Speak with other shareholders about: (OTC: HNSO), (NASDAQ: PARL), (AMEX: MCU) and (NASDAQ: RIGL) .
M2 PRESSWIRE-12 April 2007-Stockwire.com: Speak with other shareholders about: (OTC: HNSO), (NASDAQ: PARL), (AMEX: MCU) and (NASDAQ: RIGL) .C1994-2007 M2 COMMUNICATIONS LTD RDATE:12042007 AUSTIN, TX: A very interesting indicator to look for is where the money is flowing into. We have...
Issues Thursdays Stocks to Watch: ORMP! April 12, 2007.
M2 PRESSWIRE-12 April 2007-Wall Street Capital Funding LLC: Issues Thursdays Stocks to Watch: ORMP! April 12, 2007C1994-2007 M2 COMMUNICATIONS LTD RDATE:12042007 Weston, FLA. - Wall Street News Alert's "stocks to watch" this morning are: Oramed Pharmaceuticals Incorporated (OTCBB: ORMP), Healthnostics,...
- 1
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes


